

PHARMACEUTICAL FORMULATION OF GEPIRONE FOR ORAL  
ADMINISTRATION

The invention relates to a pharmaceutical formulation for oral  
5 administration with extended release properties comprising an amount of  
gepirone hydrochloride, an amount of a cellulosic polymer matrix and an  
amount of microcrystalline cellulose.

Such pharmaceutical formulations are described in EP 700 680 for use in  
10 the treatment of CNS disorders such as anxiety, depression and panic  
disorders. Gepirone is a drug which induces undesirable effects when high  
peak levels are reached. An even distribution of drug levels in blood is  
desirable to have a suitably tolerated therapeutic dose level. It was  
reported that optimal treatment of major depressive disorder was obtained  
15 with daily doses of up to 100 mg gepirone HCl (Wilcox et al;  
Psychopharmacology Bulletin). The administration of the total daily  
amount of gepirone was spread over the day by providing 20 mg gepirone  
HCl extended release tablets at intervals during the day. This was done  
not only because it was indicated in the prior art (EP 700 680) that  
20 extended release formulations can reliably be produced and have slow  
release properties when the content is at most 12% gepirone HCl of the  
total content, with a preferred maximum of 11 wt %, and the content of  
microcrystalline cellulose at least 10% with a preferred minimum of 11 wt  
%, but also because it could be expected that once-a-day high doses will  
25 be badly tolerated even when given as an extended release formulation.

Contrary to what is to be expected it was found that suitable higher  
strengths extended release tablets can be prepared and are well tolerated  
in a once a day dosage form in those patients already habituated to lower  
30 dosages.

Clearly, it is more accommodating for such patients to have a once-a-day  
formulation available.

35 This invention makes a pharmaceutical formulation according to the  
opening paragraph available in which the amount of the pharmaceutically  
acceptable cellulosic polymer matrix is from 70 to 85 wt %, the amount of  
carbohydrate binder is from 7 to 10 wt % and the amount of gepirone

hydrochloride is from 13 to 21 wt %. The formulation may optionally contain further pharmaceutically acceptable additives, such as glidants, lubricants and colorants.

- 5 The invention makes a once per day medical treatment available with gepirone HCl in a pharmaceutical formulation for oral administration having the above-defined composition. This treatment is useful and well-tolerated by those patients treated for depression or a related central nervous system disorder, who are started on a treatment regime beginning  
10 with doses of about 20 mg gepirone HCl per day, and which is gradually built up to 60-100 mg gepirone HCl per day.

A pharmaceutical formulation for oral administration is usually a tablet or a capsule. Contrary to what would have been the weight of an 80 mg  
15 tablet according to EP 700 680, tablets according to the present invention can have a total weight of at most 450 mg. Despite the high relative amount of gepirone HCl over the cellulosic polymer matrix material and also over the carbohydrate binder, oral formulations, in particular tablets, could still be made with acceptable dissolution properties of gepirone and  
20 sufficient stability during production and handling.

A pharmaceutically acceptable cellulosic polymer matrix has the function of retaining gepirone HCl so that an extended release effect is obtained. Suitable matrixes include hydroxyalkylsubstituted alkylcelluloses having a  
25 viscosity of 15,000 cps to 100,000 cps. Hydroxymethyl propylcellulose (HPMC) of grades K15M and K100M is preferred and grade K100M, Premium (Methocel) is in particular preferred. The amounts of components in the pharmaceutical formulation of the invention are expressed as weight percentage (wt %) of the total weight of the  
30 formulation, which is usually a tablet. The term alkyl as used here means a branched or unbranched saturated unsubstituted carbon chain. In view of the required viscosities, the alkyl groups referred to in this paragraph do not comprise more than 6 carbon atoms.

- 35 The term pharmaceutically acceptable for suitable additives for use in carrying out the invention refers to requirements set for pharmaceutical auxiliaries in general. These requirements with regard to safety and non-interference with the active principle in pharmaceutical formulations are

generally known to the skilled person. A standard compilation of pharmaceutically acceptable carriers and excipients can be found in the Handbook of Pharmaceutical excipients (2<sup>nd</sup> edition edited by A. Wade and P.J. Weller; Published by the American Pharmaceutical Association,

5 Washington and The Pharmaceutical Press, London in 1994). Additives to a pharmaceutical formulation, such as carriers, binders, glidants, lubricants and colorants are used for example in order to obtain certain cohesiveness, coloration and flowability of the tablets. In a preferred embodiment of this invention magnesium stearate, colloidal silicon dioxide  
10 and iron oxide pigments are used.

Glidants and lubricants are agents reducing the adhesiveness of the powder mixture or tablets during production. Methods of use of such additives are known in the art of making pharmaceutical compositions as for example described in chapter 19 of Remington's Pharmaceutical

15 Sciences (18th edition Editor A.R. Gennaro; Mack Publishing Comp; Easton, Pennsylvania).

Binders are agents used to impart cohesive properties to a pharmaceutical composition resulting in minimal loss from the pharmaceutical composition during production and handling. Carbohydrate binders are

20 for example cellulose, methylcellulose, ethylcellulose, hydroxypropylcellulose, sugars, starches, amylopectin, dextrin, maltodextrin, gums and alginates. Microcrystalline cellulose, and in particular Avicel pH 101, is a preferred binder for use in this invention.

25 The term pharmaceutical formulation for oral administration with extended release properties is used in this description to refer to the characteristics of extended release of gepirone according to the disclosure in EP 700 680. Specifically, a formulation according to the invention has a release rate of gepirone from the formulation such that about 18 to 24  
30 hours are required to attain from about 90 to about 95% absorption of gepirone.

Oral pharmaceutical formulations according to the present invention can be prepared by methods known in the art, e.g. as described in the  
35 standard reference, Gennaro et al., Remington's Pharmaceutical Sciences, (18th ed., Mack Publishing Company, 1990, see especially Part 8: Pharmaceutical Preparations and Their Manufacture). Some caution in

handling the compressed high strength formulations of this invention is advisable in order to avoid breaking and cracks in tablets.

- 5 Gepirone may be prepared by any method known in the art. Typically the compound is prepared by the methods described in US patent No. 4,423,049. Pharmaceutical extended release compositions containing gepirone are disclosed in EP 700 680. The contents of these documents are incorporated herein by reference.

- 10 The following examples will serve to illustrate how to perform the invention.

#### Example 1

- 15 Manufacturing procedure of batches of 160,000 tablets

#### Composition of tablets (Numbers in the table are amounts in mg)

Ingredients	40 mg	60 mg	80 mg	Function
Gepirone HCl	40.0	60.0	80.0	Active principle
Hydroxypropyl Methylcellulose (Methocel K100M, Premium)	290.0	290.0	290.0	Drug release controlling polymer
Microcrystalline Cellulose (Avicel pH 101)	52.12	31.0	33.7	Diluent
Euroxide yellow or red (E7055, E7056 or E7016)	0.08	1.2	3.5	Colorant
Colloidal silicon dioxide (cab-o-sil M5)	1.6	1.6	1.6	Glidant
Magnesium stearate NF	1.2	1.2	1.2	Lubricant

#### Active pre-mixture:

- 20 Transfer the colloidal silicon dioxide, NF, colorant (40 mg: Euroxide Yellow E 7056; 60 mg: Euroxide Yellow E 7055; 80 mg: Euroxide yellow E 7055 and Euroxide Red E 7016), gepirone HCl powder and 20% of hydroxypropyl methylcellulose USP in 2 cu. Ft. planetary mixer (Hobart mixer). Mix ingredients for 15 minutes in a planetary mixer (Hobart  
25 Mixer). Label as 'Active Pre-Mix'.

**Blend for slugging**

Mill the Active Pre-Mix in a Fitzmill using a perforated plate No. 0020 at high speed, impact forward to deagglomerate lumps, if any.

5

Transfer the Active Pre-Mix in a 10 cu. Ft. "V"-blender without an I-bar, while passing through #12 mesh screen and transfer the balance of 80% HPMC, microcrystalline cellulose, NF and 50% of magnesium stearate, NF in the V-blender without an I-bar. Blend ingredients in the V-blender

10 without an I bar for 24 minutes and label as "Blend for Slugging".

**Slugging**

Compress the blend into slugs using 7/8" round flat face bevelled edge (40) bevelled plain (60, 80) tooling using a rotary Kikusui-Hercules

15 compression machine.

In process controls:

Weight:	2250 mg
Hardness:	7 kp
Targeted thickness:	0.255"

**Final Blend**

Mill the slugs in an S.S. Fitzmill with screw feeder using a perforated plate  
20 No. 0093 at medium speed, knives forward and screw feeder setting of  $3.5 \pm 0.5$ . Transfer the milled mass into a 10 cu. Ft. S.S. V-blender without I-bar. Screen the balance of 50% magnesium stearate, NF through # 18 mesh and transfer also into the V-blender. Blend for 6 minutes.

25 Compress tablets with a rotary Kikusui-Libra compression machine using 0.338" X 0.405" Ovoid rectangular dies.

In process controls:

Strength, mg	40 & 60	80
Run Weight, mg	$385 \pm 27$	$410 \pm 29$
Hardness, kp	$18 \pm 4$	$20 \pm 8$
Thickness, inches	0.230 to 0.260	0.235 to 0.265

Store in tight containers untill further use or testing.

Drug release profile of tablets prepared as described in this example.  
Additional 20 mg tablets were made according to the procedure described  
in EP 700 680 for comparison of the drug release profile of the 60 and 80  
tablets according to this invention,:

**Gepirone release pattern of tablets** (Numbers in the table represent the percentage dissolution of the theoretical content of the tablets)

Released after: →	1 hr	5 hr	12 hr	20 hr	recovery
20 mg tablets	19	49	77	93	102
40 mg tablets	21	50	77	93	100
60 mg tablets	21	51	81	97	102
80 mg tablets	22	52	80	96	101

### Example 2

5

For upscaling the manufacturing for batches of 800,000 tablets certain adaptations were applied:

Thus, procedures are according to the methods described in example 1,  
 10 but the active pre-mix is blended in a 340 qt. AZMF Glen mixer for 28 minutes, the size of the V-blender used is 30 cu. Ft. and final blending is done for 7 minutes. Tablets had similar properties as measured in example 1. Special attention is given to the problem of friability of the 80 mg strength tablets. It is preferred to compress 80 mg tablets at a speed of  
 15 the compression machine of 20 rotations per minute, i.e. in general at a speed of less than 30 rpm, set at the tablet compression machine in order to reduce the number of tablets with cracks.